The BRCA1 and BRCA2 (breast cancer 1 and 2) genes are two genes found within everyone’s normal genetic material. When mutations, or gene alterations, are found within these genes, the mutations can cause an increased risk for several specific types of cancer. The BRCA mutations can be passed down through a family and are associated with hereditary breast cancer and ovarian cancer. Genetic testing for BRCA1 and BRCA2 mutations is available for those individuals at increased risk and can help provide information about the risk for developing breast cancer, ovarian or other cancers.
Within the first few days after a baby is born, he or she is examined by a team of physicians and nurses. Part of the exam includes the collection of blood. A portion of this blood can be used to screen for inherited disorders. Although rare, inherited disorders are serious and the complications can be devastating. Inherited disorders that go undetected until symptoms develop can cause lifelong complications, including mental retardation, motor impairment and physical disability. Some can lead to death. Newborns that are screened and diagnosed early can receive treatment before symptoms develop. These children can lead normal, healthy lives as a result of early detection. For more information about the test please download the brochure and consult with your physician.
InformaSeq Prenatal Test assesses the risk of three fetal trisomies by measuring the relative amount of chromosomes in maternal blood. This test includes an option to evaluate the Y-chromosome through which fetal sex can be determined (informaSeq with Y analysis) and an option for testing the most common sex chromosomes (informaSeq with XY analysis).
When people review their family’s medical history, they may find a number of relatives who have had various types of cancer. This may be due to the their relatives having certain risk factors in common, such as smoking, or it may be due to inherited gene mutation that can increase their risk for developing cancer. VistaSeq provides an assessment of genetic mutations with a panel of 27 genes known to be associated with hereditary cancer syndromes. For more information about the test please download the brochure and consult with your physician.